CCR1 blockade and myeloma bone disease.
In this issue of Blood, Dairaghi and colleagues demonstrate the efficacy of a potent and orally bioavailable inhibitor of CCR1, one of the receptors for the chemokine CCL3/MIP-1, in a mouse model of multiple myeloma (MM) and MM bone disease. They show CCX721 to be a highly selective and efficient inhibitor of CCR1 and in turn a suppressor of osteoclastic activity, osteolytic lesions, and disease burden in a preclinical MM model.
Mcgill University.
Michael
M
Sebag
D000818:Animals; D018925:Chemokines / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D010014:Osteolysis / Q000188:drug therapy*; D054389:Receptors, CCR1 / Q000037:antagonists & inhibitors*; D047368:Tumor Burden / Q000187:drug effects*
C515301:Ccr1 protein, mouse; D018925:Chemokines; D054389:Receptors, CCR1